Endo Health Solutions Announces Departure Of Chief Financial Officer
MALVERN, Pa., May 29, 2013 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) today announced that Alan G. Levin, Executive Vice President & Chief Financial Officer, will be leaving the Company. Mr. Levin will continue in his current role until the fall, while a search is conducted for his successor.
The Board of Directors has formed a search committee and engaged a leading search firm to assist in an external search for a new CFO.
Rajiv De Silva, Chief Executive Officer, said, "The Board and I want to thank Alan for his dedicated service and significant contributions to building Endo into one of the leading public diversified healthcare companies. I also want to recognize Alan's contributions to the ongoing assessment of the company's strategy and operations, which I launched upon my arrival at Endo. We expect a smooth transition and are confident in the plans we are putting in place to position Endo for the future and drive shareholder value."
Alan Levin said, "Endo is a great company, and I am confident that it will do well in this next phase in its evolution. I am proud to have played a role in its growth and diversification during my tenure as Chief Financial Officer. After twenty years in corporate executive positions—the last four of which have been at Endo, I look forward to a fulfilling new chapter in my life and plan to be active in corporate board service and philanthropy, while traveling and spending more time with my family."
Endo Health Solutions Inc. (Endo) is a U.S.-based diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. Through our operating companies: AMS, Endo Pharmaceuticals, HealthTronics and Qualitest, Endo is dedicated to improving care through a combination of branded products, generics, devices, technology and services that creates value for patients, providers and payers alike. Learn more at www.endo.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
SOURCE Endo Health Solutions Inc.
More by this Source
Endo Health Solutions Announces Receipt of Requisite Consents and Expiration of Consent Solicitations Relating to its 7% Senior Notes Due 2019, 7.00% Senior Notes Due 2020 and 7 1/4% Senior Notes Due 2022
Nov 27, 2013, 18:36 ET
Endo Health Solutions to Present at the 2013 Credit Suisse Healthcare Conference
Nov 11, 2013, 15:15 ET
Endo Health Solutions to Present at the Stifel Nicolaus 2013 Healthcare Conference
Sep 06, 2013, 15:23 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.